Clinical features and prognosis of juvenile myelomonocytic leukemia: an analysis of 63 cases.
10.7499/j.issn.1008-8830.2209129
- Author:
Wen-Yu YANG
1
;
Li-Peng LIU
1
;
Fang LIU
1
;
Ben-Quan QI
1
;
Li-Xian CHANG
1
;
Li ZHANG
1
;
Xiao-Juan CHEN
1
;
Yao ZOU
1
;
Yu-Mei CHEN
1
;
Ye GUO
1
;
Xiao-Fan ZHU
1
Author Information
1. Department of Pediatrics, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
- Publication Type:Journal Article
- Keywords:
Child;
Clinical feature;
Gene mutation;
Juvenile myelomonocytic leukemia;
Prognosis
- MeSH:
Child;
Humans;
Male;
Female;
Child, Preschool;
Leukemia, Myelomonocytic, Juvenile/therapy*;
Prognosis;
Genetic Testing;
Mutation;
Hematopoietic Stem Cell Transplantation
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(3):265-271
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the clinical features of juvenile myelomonocytic leukemia (JMML) and their association with prognosis.
METHODS:Clinical and prognosis data were collected from the children with JMML who were admitted from January 2008 to December 2016, and the influencing factors for prognosis were analyzed.
RESULTS:A total of 63 children with JMML were included, with a median age of onset of 25 months and a male/female ratio of 3.2∶1. JMML genetic testing was performed for 54 children, and PTPN11 mutation was the most common mutation and was observed in 23 children (43%), among whom 19 had PTPN11 mutation alone and 4 had compound PTPN11 mutation, followed by NRAS mutation observed in 14 children (26%), among whom 12 had NRAS mutation alone and 2 had compound NRAS mutation. The 5-year overall survival (OS) rate was only 22%±10% in these children with JMML. Of the 63 children, 13 (21%) underwent hematopoietic stem cell transplantation (HSCT). The HSCT group had a significantly higher 5-year OS rate than the non-HSCT group (46%±14% vs 29%±7%, P<0.05). There was no significant difference in the 5-year OS rate between the children without PTPN11 gene mutation and those with PTPN11 gene mutation (30%±14% vs 27%±10%, P>0.05). The Cox proportional-hazards regression model analysis showed that platelet count <40×109/L at diagnosis was an influencing factor for 5-year OS rate in children with JMML (P<0.05).
CONCLUSIONS:The PTPN11 gene was the most common mutant gene in JMML. Platelet count at diagnosis is associated with the prognosis in children with JMML. HSCT can improve the prognosis of children with JMML.
